A long-term commitment to LEO Pharma
The LEO Foundation was created in 1984 to secure LEO Pharma a long-term basis for the company's continued development as an independent, international and research-based pharmaceutical company. The LEO Foundation owns all the shares in LEO Pharma and is totally independent of heirs, outside shareholders or other interests.
The LEO Foundation's overall objective is to ensure that LEO Pharma, now and in the future is a significant and responsible player in the research, development and marketing of pharmaceuticals - to the benefit of patients around the world and the company's own continued development.
The long-term owner perspective of the LEO Foundation is the reason why LEO Pharma - with skill, commitment and passion - has been able to evolve into a world leader in research, development and marketing of pharmaceuticals for the treatment of skin diseases. A company that today employs more than 5,000 people in over 60 countries in research, development, production and sales.
The LEO Foundation is unique among its peers as it maintains total independence of outside interests. No family members, external shareholders or others receive support or dividends.
The Foundation can therefore concentrate fully on its core mission - the sole reason for the foundation's existence - which is to operate and develop the company LEO Pharma.
Ambition, vision & passion
Dr.jur.h.c. Knud Abildgaard
The success of LEO Pharma is the result of the dedicated and focused joint efforts of many people.
Even so, in the history of the company, one person stands out. A person whose ambition, vision and passion proved paramount for LEO Pharma and led him to create the LEO Foundation and thus a unique underpinning for the company's continued development.
That person was dr.jur.h.c. Knud Abildgaard who took control of the company in 1939, succeeding LEO Pharma's founder, pharmacist August Kongsted.
Read more on the history of the LEO Foundation.